Title
Category
Credits
Event date
Cost
Parkinson's Disease Psychosis: Review of Neuropsychiatric Complications
  • Parkinson Disease
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
An average of 35% of patients diagnosed with Parkinson’s disease experience Parkinson’s psychosis. Recognition and diagnosis of this nonmotor manifestation is critical in choosing the best treatment strategy and managing these symptoms.
Tweetorial: CKD in Real-World Practice: Examine a Patient Case
  • Renal Disease
  • Cardiology
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Experts examine a patient case study as a way of translating guideline-based screening recommendations and current therapies that protect T2D patients from CKD progression in real-world practice.
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
  • Depression
  • Major Depressive Disorder
  • Women’s Mental Health
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
$0.00
Studies evaluating neuroactive steroid GABA-A receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD.
Seizure Clusters in the Real World: The Call to Arms
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies.
Therapeutic Advances for Epileptic Seizure Rescue
  • Epilepsy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications.
Diagnosing and Treating Alzheimer Disease During the Early Stage
  • Alzheimer Disease
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
  • Schizophrenia/ Schizoaffective Disorders
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.
Tweetorial: Parkinson’s Disease Psychosis: Best Practices for Diagnosing PDP
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more.
Tweetorial: Parkinson’s Disease Psychosis: Current Therapies for Patients with PDP
  • Parkinson Disease
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.

Pages